Resultats de la cerca - Ivana Gojo

Refinar resultats
  1. 1
    Immune escape and immunotherapy of acute myeloid leukemia

    Immune escape and immunotherapy of acute myeloid leukemia per Luca Vago, Ivana Gojo

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Myeloid cell factor–1 is a critical survival factor for multiple myeloma

    Myeloid cell factor–1 is a critical survival factor for multiple myeloma per Bin Zhang, Ivana Gojo, Robert G. Fenton

    Publicat 2002
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia

    Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia per Hanna A. Knaus, Christopher G. Kanakry, Leo Luznik, Ivana Gojo

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias

    Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias per Lisa A. Tobin, Caroline Robert, Aaron P. Rapoport, Ivana Gojo, Maria R. Baer, Alan E. Tomkinson, Feyruz V. Rassool

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study

    Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study per Borislav A. Alexiev, Wenle Wang, Yi Ning, Saranya Chumsri, Ivana Gojo, William H. Rodgers, Sanford A. Stass, Xianfeng Zhao

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin

    Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin per Carine Robert, Pratik Nagaria, Nisha R. Pawar, Adeoluwa Adewuyi, Ivana Gojo, David J. Meyers, Philip A. Cole, Feyruz V. Rassool

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fluda... per Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low

    Publicat 2007
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

    Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome per Ivana Gojo, Alexander E. Perl, Selina M. Luger, Maria R. Baer, Kelly J. Norsworthy, Kenneth S. Bauer, Michael Tidwell, Stephanie Fleckinger, Martin Carroll, Edward A. Sausville

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide

    Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclo... per Shannon R. McCurdy, Brian Iglehart, Denise Batista, Christopher D. Gocke, Yi Ning, Hanna A. Knaus, Annette M. Jackson, Mary S. Leffell, Leo Luznik, Ivana Gojo

    Publicat 2016
    Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  10. 10
    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias

    Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias per Ken Shiozawa, Takeo Nakanishi, Ming Tan, Hong-Bin Fang, Wen-chyi Wang, Martin J. Edelman, David P. Carlton, Ivana Gojo, Edward A. Sausville, Douglas D. Ross

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

    A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome per Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Christopher Bredeson, Lisa Kujawski, Allen S. Yang, Peter Marks, Paul Frankel, Xing Sun, Alessandra Tosolini, Joseph Eid, Gregory M. Lubiniecki, Jean–Pierre J. Issa

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy per Hanna A. Knaus, Sofia Berglund, Hubert Hackl, Amanda L. Blackford, Joshua F. Zeidner, Raul Montiel‐Esparza, Rupkatha Mukhopadhyay, Katrina Vanura, Bruce R. Blazar, Judith E. Karp, Leo Luznik, Ivana Gojo

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia

    Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid... per Ivana Gojo, Ming Tan, Hong‐Bin Fang, Mariola Sadowska, Rena G. Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rahul Srivastava, Igor Espinoza‐Delgado, Douglas D. Ross

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide per Laura Schoch, Kenneth R. Cooke, Nina D. Wagner‐Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark J. Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia

    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia per Steven D. Gore, Ivana Gojo, Mikkael A. Sekeres, Lawrence E. Morris, Marcel P. Devetten, Katarzyna Jamieson, Robert L. Redner, R.J. Arceci, Ibitayo Owoeye, Tianna Dauses, Esther Schachter-Tokarz, Robert E. Gallagher

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) per Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian, Amy O. Johnson‐Levonas, Craig Fancourt, Raymond W. Lam, Mary Jones, Clayton D. Knox, Shelonitda Rose, Payal Patel, Raoul Tibes

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing

    The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing per W. Brian Dalton, Eric Helmenstine, Lisa Pieterse, Bing Li, Christopher D. Gocke, Joshua Donaldson, Zhijian Xiao, Lukasz P. Gondek, Gabriel Ghiaur, Ivana Gojo, B. Douglas Smith, Mark J. Levis, Amy E. DeZern

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias per Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms per Joshua F. Zeidner, J. E. Karp, Amanda L. Blackford, B. D. Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Judith M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo per Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Andrew McNally, Ivana Gojo, Judith E. Karp, Ruben A. Mesa, Lisa Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: